These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 25716150)

  • 1. Influence of P-Glycoprotein Inhibition or Deficiency at the Blood-Brain Barrier on (18)F-2-Fluoro-2-Deoxy-D-glucose ( (18)F-FDG) Brain Kinetics.
    Tournier N; Saba W; Goutal S; Gervais P; Valette H; Scherrmann JM; Bottlaender M; Cisternino S
    AAPS J; 2015 May; 17(3):652-9. PubMed ID: 25716150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [(18)F]FDG is not transported by P-glycoprotein and breast cancer resistance protein at the rodent blood-brain barrier.
    Wanek T; Traxl A; Bankstahl JP; Bankstahl M; Sauberer M; Langer O; Kuntner C
    Nucl Med Biol; 2015 Jul; 42(7):585-9. PubMed ID: 25823393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [¹¹C]befloxatone brain kinetics is not influenced by Bcrp function at the blood-brain barrier: a PET study using Bcrp TGEM knockout rats.
    Hosten B; Boisgard R; Jacob A; Goutal S; Saubaméa B; Dollé F; Scherrmann JM; Cisternino S; Tournier N
    Eur J Pharm Sci; 2013 Nov; 50(3-4):520-5. PubMed ID: 23981334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of P-glycoprotein in intestinal transport versus the BBB transport of tetraphenylphosphonium.
    Swed A; Eyal S; Madar I; Zohar-Kontante H; Weiss L; Hoffman A
    Mol Pharm; 2009; 6(6):1883-90. PubMed ID: 19722701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
    Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
    Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and Preclinical Evaluation of Three Novel Fluorine-18 Labeled Radiopharmaceuticals for P-Glycoprotein PET Imaging at the Blood-Brain Barrier.
    Savolainen H; Cantore M; Colabufo NA; Elsinga PH; Windhorst AD; Luurtsema G
    Mol Pharm; 2015 Jul; 12(7):2265-75. PubMed ID: 26043236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transport of selected PET radiotracers by human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2): an in vitro screening.
    Tournier N; Valette H; Peyronneau MA; Saba W; Goutal S; Kuhnast B; Dollé F; Scherrmann JM; Cisternino S; Bottlaender M
    J Nucl Med; 2011 Mar; 52(3):415-23. PubMed ID: 21321274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier.
    Nagasaka Y; Oda K; Iwatsubo T; Kawamura A; Usui T
    Biopharm Drug Dispos; 2012 Sep; 33(6):304-15. PubMed ID: 22847220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging the Impact of the P-Glycoprotein (ABCB1) Function on the Brain Kinetics of Metoclopramide.
    Pottier G; Marie S; Goutal S; Auvity S; Peyronneau MA; Stute S; Boisgard R; Dollé F; Buvat I; Caillé F; Tournier N
    J Nucl Med; 2016 Feb; 57(2):309-14. PubMed ID: 26585058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.
    Vlaming ML; Läppchen T; Jansen HT; Kivits S; van Driel A; van de Steeg E; van der Hoorn JW; Sio CF; Steinbach OC; DeGroot J
    Nucl Med Biol; 2015 Nov; 42(11):833-41. PubMed ID: 26264927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates.
    Damont A; Goutal S; Auvity S; Valette H; Kuhnast B; Saba W; Tournier N
    Eur J Pharm Sci; 2016 Aug; 91():98-104. PubMed ID: 27283486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissimilar Effect of P-Glycoprotein and Breast Cancer Resistance Protein Inhibition on the Distribution of Erlotinib to the Retina and Brain in Humans and Mice.
    Biali ME; Auvity S; Cisternino S; Smirnova M; Hacker M; Zeitlinger M; Mairinger S; Tournier N; Bauer M; Langer O
    Mol Pharm; 2023 Nov; 20(11):5877-5887. PubMed ID: 37883694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elucidation of the Impact of P-glycoprotein and Breast Cancer Resistance Protein on the Brain Distribution of Catechol-
    Bicker J; Fortuna A; Alves G; Soares-da-Silva P; Falcão A
    Drug Metab Dispos; 2017 Dec; 45(12):1282-1291. PubMed ID: 28916530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier.
    Ose A; Kusuhara H; Yamatsugu K; Kanai M; Shibasaki M; Fujita T; Yamamoto A; Sugiyama Y
    Drug Metab Dispos; 2008 Feb; 36(2):427-34. PubMed ID: 18039806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.
    Chen Y; Agarwal S; Shaik NM; Chen C; Yang Z; Elmquist WF
    J Pharmacol Exp Ther; 2009 Sep; 330(3):956-63. PubMed ID: 19491323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.
    Breedveld P; Pluim D; Cipriani G; Wielinga P; van Tellingen O; Schinkel AH; Schellens JH
    Cancer Res; 2005 Apr; 65(7):2577-82. PubMed ID: 15805252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein.
    Lee YJ; Kusuhara H; Jonker JW; Schinkel AH; Sugiyama Y
    J Pharmacol Exp Ther; 2005 Jan; 312(1):44-52. PubMed ID: 15448171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Subchronic Intravenous Morphine Infusion and Naloxone-Precipitated Morphine Withdrawal on P-gp and Bcrp at the Rat Blood-Brain Barrier.
    Chaves C; Gómez-Zepeda D; Auvity S; Menet MC; Crété D; Labat L; Remião F; Cisternino S; Declèves X
    J Pharm Sci; 2016 Jan; 105(1):350-8. PubMed ID: 26554626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid can be used as a surrogate to assess brain exposures of breast cancer resistance protein and P-glycoprotein substrates.
    Xiao G; Black C; Hetu G; Sands E; Wang J; Caputo R; Rohde E; Gan LS
    Drug Metab Dispos; 2012 Apr; 40(4):779-87. PubMed ID: 22266779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.